Latest Company Intelligence

• LabCorp Extends Orchid Cellmark Tender For Fifth Time 
  The Wall Street Journal  | Sep 12,'11
  Laboratory Corp. of America Holdings (LH) extended its $84 million cash tender offer for Orchid Cellmark Inc. (ORCH) a fifth time as the medical-testing services provider continues to cooperate with the Federal Trade Commission's request for further information. LabCorp said in April it would acquire DNA-testing services company Orchid in an effort to strengthen its presence in the U.S.
• Abbott Taps Six Labs to Offer Its New Vysis ALK FISH Dx for NSCLC 
  The Sample - GenomeWeb Daily News  | Sep 8,'11
  Abbott Molecular has begun shipping its newly cleared Vysis ALK Break Apart FISH probe kit test. The assay, approved last week to detect rearrangements of the anaplastic lymphoma kinase, or ALK, gene in patients with non-small-cell lung cancer, will be available through the following labs: Cynogen Laboratory, LabCorp, the University of Colorado at Boulder, the Cleveland Clinic, and at
• LabCorp Extends Payor Deal With UnitedHealthcare 
  The Sample - GenomeWeb Daily News  | Sep 8,'11
  A large international consortium reported online in Nature Genetics that it has identified a half-dozen risk loci for type 2 diabetes in the South Asian population that had previously not been found. The search uncovered both new and known type 2 diabetes-associated loci, along with variants associated with related processes such as insulin sensitivity and the function of
• Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011) -- Judge Moore's Dissent 
  Patent Docs  | Sep 7,'11
  The Federal Circuit majority decision in Classen Immunotherapies, Inc. v. Biogen IDEC engendered a strong dissent from Judge Moore on almost every aspect of that decision. Judge Moore disagreed with the majority's opinion that the claims were patent-eligible, that the issue of inherent anticipation was not properly before the Court, and that certain activities by defendant
• LabCorp Settles with State of California Over Kickback Marketing Scheme–Lab Wars 
  The Medical Quack  | Sep 1,'11
  Both Quest and LabCorp were doing this and this is funny in the information here from BNET that he had the actual PowerPoint slides. Quest settled up for $241 million for their portion of gaining market share. Quest does not appear to be done yet though as now they have a whistle blower alleging even more fraud, maybe a billion and this case is a little more complex and has to do
• LabCorp Pays California $50M to Settle Medicaid-Fraud Suit 
  The Sample - GenomeWeb Daily News  | Aug 31,'11
  LabCorp will pay California $49.5 million to settle a Medicaid-fraud suit the state filed after being tipped off by a whistleblower at a rival lab. The settlement goes back to 2005 when northern-California-based rival Hunter Laboratories told Medi-Cal , the state's Medicaid program, that LabCorp was charging it more than five times what it billed other customers for certain tests. ▪

• To See More On FirstRain, Request A Trial >